Review of the status of neoadjuvant therapy in HER2-positive breast cancer

被引：18

作者：

Dowling, Gavin P. ^{[1
,2
,3
]}

Keelan, Stephen ^{[2
,3
]}

Toomey, Sinead ^{[1
]}

Daly, Gordon R. ^{[2
,3
]}

Hennessy, Bryan T. ^{[1
]}

Hill, Arnold D. K. ^{[2
,3
]}

机构：

[1] Royal Coll Surgeons Ireland, Dept Mol Med, Med Oncol Lab, Dublin, Ireland

[2] Royal Coll Surgeons Ireland, Dept Surg, Dublin, Ireland

[3] Beaumont Hosp, Dept Surg, Dublin, Ireland

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 13卷

关键词：

neoadjuvant therapy; breast cancer; HER2 (human epidermal growth factor 2); targeted therapy; biomarker; antibody-drug-conjugates; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY PLUS TRASTUZUMAB; LONG-TERM OUTCOMES; ADJUVANT TRASTUZUMAB; OPEN-LABEL; SURVIVAL OUTCOMES; FINAL ANALYSIS; FOLLOW-UP; LAPATINIB; PERTUZUMAB;

D O I：

10.3389/fonc.2023.1066007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PurposeThe development of human epidermal growth factor receptor 2 (HER2)-directed therapies has revolutionized the treatment of HER2-positive breast cancer. The aim of this article is to review the continually evolving treatment strategies in the neoadjuvant setting of HER2-positive breast cancer, as well as the current challenges and future perspectives. MethodsSearches were undertaken on PubMed and Clinicaltrials.gov for relevant publications and trials. FindingsThe current standard of care in high-risk HER2-positive breast cancer is to combine chemotherapy with dual anti-HER2 therapy, for a synergistic anti-tumor effect. We discuss the pivotal trials which led to the adoption of this approach, as well as the benefit of these neoadjuvant strategies for guiding appropriate adjuvant therapy. De-escalation strategies are currently being investigated to avoid over treatment, and aim to safely reduce chemotherapy, while optimizing HER2-targeted therapies. The development and validation of a reliable biomarker is essential to enable these de-escalation strategies and personalization of treatment. In addition, promising novel therapies are currently being explored to further improve outcomes in HER2-positive breast cancer.

引用

页数：10

共 99 条

[41] 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia Valeria ;

Magazzu, Domenico ;

McNally, Virginia ;

Douthwaite, Hannah ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2016, 17 (06) :791-800

[42] Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort [J].

Gianni, Luca ;

Eiermann, Wolfgang ;

Semiglazov, Vladimir ;

Lluch, Ana ;

Tjulandin, Sergei ;

Zambetti, Milvia ;

Moliterni, Angela ;

Vazquez, Federico ;

Byakhov, Mikhail J. ;

Lichinitser, Mikhail ;

Climent, Miguel Angel ;

Ciruelos, Eva ;

Ojeda, Belen ;

Mansutti, Mauro ;

Bozhok, Alla ;

Magazzu, Domenico ;

Heinzmann, Dominik ;

Steinseifer, Jutta ;

Valagussa, Pinuccia ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (06) :640-647

[43] Systemic Therapy for Advanced Human 3 Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update [J].

Giordano, Sharon H. ;

Temin, Sarah ;

Chandarlapaty, Sarat ;

Crews, Jennie R. ;

Kirshner, Jeffrey J. ;

Krop, Ian E. ;

Lin, Nancy U. ;

Patt, Debra A. ;

Perlmutter, Jane ;

Ramakrishna, Naren ;

Davidson, Nancy E. ;

Franzoi, Maria Alice B. ;

Anders, Carey K. ;

Ikawa, Aki .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) :2612-+

[44] Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials [J].

Guarneri, V ;

Griguolo, G. ;

Miglietta, F. ;

Conte, P. F. ;

Dieci, M., V ;

Girardi, F. .

ESMO OPEN, 2022, 7 (02)

[45] Original Research Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial [J].

Guarneri, Valentina ;

V. Dieci, Maria ;

Griguolo, Gaia ;

Miglietta, Federica ;

Girardi, Fabio ;

Bisagni, Giancarlo ;

Generali, Daniele G. ;

Cagossi, Katia ;

Sarti, Samanta ;

Frassoldati, Antonio ;

Gianni, Lorenzo ;

Cavanna, Luigi ;

Pinotti, Graziella ;

Musolino, Antonino ;

Piacentini, Federico ;

Cinieri, Saverio ;

Prat, Aleix ;

Conte, PierFranco .

EUROPEAN JOURNAL OF CANCER, 2021, 153 :133-141

[46] Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis [J].

Gunasekara, Agampodi Danushi M. ;

Anothaisintawee, Thunyarat ;

Youngkong, Sitaporn ;

Ha, Nguyen T. ;

McKay, Gareth J. ;

Attia, John ;

Thakkinstian, Ammarin .

CANCERS, 2022, 14 (03)

[47] Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer A Phase 2 Randomized Clinical Trial [J].

Hatschek, Thomas ;

Foukakis, Theodoros ;

Bjohle, Judith ;

Lekberg, Tobias ;

Fredholm, Hanna ;

Elinder, Ellinor ;

Bosch, Ana ;

Pekar, Gyula ;

Lindman, Henrik ;

Schiza, Aglaia ;

Einbeigi, Zakaria ;

Adra, Jamila ;

Andersson, Anne ;

Carlsson, Lena ;

Dreifaldt, Ann Charlotte ;

Isaksson-Friman, Erika ;

Agartz, Susanne ;

Azavedo, Edward ;

Gryback, Per ;

Hellstrom, Mats ;

Johansson, Hemming ;

Maes, Claudia ;

Zerdes, Ioannis ;

Hartman, Johan ;

Brandberg, Yvonne ;

Bergh, Jonas .

JAMA ONCOLOGY, 2021, 7 (09) :1360-1367

[48] Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer [J].

Huober, Jens ;

Holmes, Eileen ;

Baselga, Jose ;

de Azambuja, Evandro ;

Untch, Michael ;

Fumagalli, Debora ;

Sarp, Severine ;

Lang, Istvan ;

Smith, Ian ;

Boyle, Frances ;

Xu, Binghe ;

Lecocq, Christophe ;

Wildiers, Hans ;

Jouannaud, Christelle ;

Hackman, John ;

Dasappa, Lokanatha ;

Ciruelos, Eva ;

Toral Pena, Juan Carlos ;

Adamchuk, Hryhoriy ;

Hickish, Tamas ;

de la Pena, Lorena ;

Jackisch, Christian ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine ;

Di Cosimo, Serena .

EUROPEAN JOURNAL OF CANCER, 2019, 118 :169-177

[49] ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer [J].

Hurvitz, Sara A. ;

Bachelot, Thomas ;

Bianchini, Giampaolo ;

Harbeck, Nadia ;

Loi, Sherene ;

Park, Yeon Hee ;

Prat, Aleix ;

Gilham, Leslie ;

Boulet, Thomas ;

Gochitashvili, Nino ;

Monturus, Estefania ;

Lambertini, Chiara ;

Nyawira, Beatrice ;

Knott, Adam ;

Restuccia, Eleonora ;

Schmid, Peter .

FUTURE ONCOLOGY, 2022, 18 (32) :3563-3572

[50] Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study [J].

Hurvitz, Sara A. ;

Martin, Miguel ;

Jung, Kyung Hae ;

Huang, Chiun-Sheng ;

Harbeck, Nadia ;

Valero, Vicente ;

Stroyakovskiy, Daniil ;

Wildiers, Hans ;

Campone, Mario ;

Boileau, Jean-Francois ;

Fasching, Peter A. ;

Afenjar, Karen ;

Spera, Gonzalo ;

Lopez-Valverde, Vanesa ;

Song, Chunyan ;

Trask, Peter ;

Boulet, Thomas ;

Sparano, Joseph A. ;

Symmans, W. Fraser ;

Thompson, Alastair M. ;

Slamon, Dennis .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) :2206-+

← 1 2 3 4 5 6 7 8 9 10 →